Company

Entera Bio Ltd.

Headquarters: Jerusalem, Israel

Employees: 18

NASDAQ: ENTX -4.91%

Market Cap

$279,154

USD as of Jan. 1, 2024

Market Cap History

Entera Bio Ltd. market capitalization over time

Evolution of Entera Bio Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Entera Bio Ltd.

Detailed Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Entera Bio Ltd. has the following listings and related stock indices.


Stock: NASDAQ: ENTX wb_incandescent

Details

Headquarters:

Minrav Building

Fifth Floor Kiryat Hadassah PO Box 12117

Jerusalem, 9112002

Israel

Phone: 972 2 532 7151